JP2024540318A - Cd38阻害剤としてのn-(4-アミノシクロヘキシル)ピリミジン-4-カルボキサミド誘導体 - Google Patents

Cd38阻害剤としてのn-(4-アミノシクロヘキシル)ピリミジン-4-カルボキサミド誘導体 Download PDF

Info

Publication number
JP2024540318A
JP2024540318A JP2024526654A JP2024526654A JP2024540318A JP 2024540318 A JP2024540318 A JP 2024540318A JP 2024526654 A JP2024526654 A JP 2024526654A JP 2024526654 A JP2024526654 A JP 2024526654A JP 2024540318 A JP2024540318 A JP 2024540318A
Authority
JP
Japan
Prior art keywords
methyl
imidazol
mmol
cyclohexyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540318A5 (cg-RX-API-DMAC7.html
Inventor
ブルリ,ローランド
ドイル,ケヴィン
Original Assignee
セレヴァンス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレヴァンス,インコーポレイテッド filed Critical セレヴァンス,インコーポレイテッド
Publication of JP2024540318A publication Critical patent/JP2024540318A/ja
Publication of JP2024540318A5 publication Critical patent/JP2024540318A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024526654A 2021-11-09 2022-11-09 Cd38阻害剤としてのn-(4-アミノシクロヘキシル)ピリミジン-4-カルボキサミド誘導体 Pending JP2024540318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116077.5 2021-11-09
GB202116077 2021-11-09
PCT/GB2022/052833 WO2023084206A1 (en) 2021-11-09 2022-11-09 N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors

Publications (2)

Publication Number Publication Date
JP2024540318A true JP2024540318A (ja) 2024-10-31
JP2024540318A5 JP2024540318A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=84360092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526654A Pending JP2024540318A (ja) 2021-11-09 2022-11-09 Cd38阻害剤としてのn-(4-アミノシクロヘキシル)ピリミジン-4-カルボキサミド誘導体

Country Status (6)

Country Link
US (1) US20250019369A1 (cg-RX-API-DMAC7.html)
EP (1) EP4430034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540318A (cg-RX-API-DMAC7.html)
CN (1) CN118317955A (cg-RX-API-DMAC7.html)
CA (1) CA3236793A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023084206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4532483A1 (en) * 2022-06-02 2025-04-09 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090857A1 (zh) * 2024-10-29 2026-05-07 甫康(上海)健康科技有限责任公司 一种多取代的氨基喹啉类化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途

Also Published As

Publication number Publication date
EP4430034A1 (en) 2024-09-18
CN118317955A (zh) 2024-07-09
CA3236793A1 (en) 2023-05-19
WO2023084206A1 (en) 2023-05-19
US20250019369A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
EP3405465B1 (en) Irak4 inhibiting agents
WO2023084206A1 (en) N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
EP2763978B1 (en) Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors
KR20090014347A (ko) 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물
CA2957898C (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
US7579471B2 (en) Tropane derivatives useful in therapy
EP4713323A1 (en) 3-carbonyl imidazo[1,5-a]pyridine derivatives for use as cd38 inhibitors for the treatment of cns disorders
WO2019241751A1 (en) Ssao inhibitors and uses thereof
EP4741397A1 (en) Fused tricyclic compound, and preparation method therefor and use thereof
US20170119795A1 (en) Fused triterpene compounds and uses thereof
US20240246961A1 (en) Autotaxin inhibitor compounds
EP4482579B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
DE60101137T2 (de) N-Benzensulfonyl-L-Prolin Derivate und deren Verwendung als Bradykinin Antagonisten
US20130310396A1 (en) Thiazolidine derivatives and their therapeutic use
US20250320189A1 (en) New derivatives for treating trpm3 mediated disorders
WO2024236315A1 (en) 1,3-thiazole and 1,2,4-thiadiazole derivatives for use as cd38 inhibitors for the treatment of cns disorders
EP4532014A1 (en) Heterobicyclic amides as inhibitors of cd38
US20240059677A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
JP2006511528A (ja) Nr2bレセプターアンタゴニストとしての2−ピリジル及び2−ピリミジルシクロアルキレンアミド化合物
WO2025043148A1 (en) Emopamil-binding protein inhibitors and uses thereof
JP2025504889A (ja) エモパミル結合タンパク質阻害剤及びその使用
WO2026059895A1 (en) Substituted tricyclicheterocyclylsulfonamide derivatives and uses thereof
TW202606708A (zh) 雜環gpr52調節劑及其使用方法
CN113735825A (zh) 1,2,3,6-四氢吡啶类化合物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110